PPARD

Across TCGA pan-cancer cohorts, PPARD Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PPARD data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PPARD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPARD expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

OV, LIHC, and SKCM are the cancer types where PPARD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.308	0.691	.036	18	view →
LIHC	OS	Median	All	0.118	0.783	<.001	18	view →
SKCM	OS	Median	All	0.251	0.784	<.001	15	view →
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
LUSC	OS	Median	All	0.138	0.818	.003	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.413	.038	4	view →
SCLC	DFS	Median	II,III,IV	0.164	0.561	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PPARD–OV (OS)

Open the OV breakdown →